Dataset Information

The Incidence of Diabetic Ketoacidosis During "Emerging Adulthood" in the USA and Canada: a Population-Based Study.

ABSTRACT:

Background

As children with diabetes transition to adulthood, they may be especially vulnerable to diabetic ketoacidosis (DKA). Cross-national comparisons may inform efforts to avoid this complication.

Objective

To compare DKA hospitalization rates in the USA and Manitoba, Canada, during the vulnerable years known as "emerging adulthood."

Design

Cross-sectional study using inpatient administrative databases in the USA (years 1998-2014) and Manitoba, Canada (years 2003-2013).

Participants

Individuals aged 12-30 years hospitalized with DKA, identified using ICD-9 (USA) or ICD-10 codes (Manitoba).

Main measures

DKA hospitalization rates per 10,000 population by age (with a focus on those aged 15-17 vs. 19-21). Admissions were characterized by gender, socioeconomic status, year of hospitalization, and mortality during hospitalization.

Key results

The DKA rate was slightly higher in the USA among those aged 15-17: 4.8 hospitalizations/10,000 population vs. 3.7/10,000 in Manitoba. Among those aged 19-21, the DKA hospitalization rate rose 90% in the USA to 9.2/10,000, vs. 23% in Manitoba, to 4.5/10,000. In both the USA and Manitoba, rates were higher among those from poorer areas, and among adolescent girls compared with adolescent boys. DKA admissions rose gradually during the period under study in the USA, but not in Manitoba.

Conclusions

In years of "emerging adulthood," the Canadian healthcare system appears to perform better than that of the USA in preventing hospitalizations for DKA. Although many factors likely contribute to this difference, universal and seamless coverage over the lifespan in Canada may contribute.

SUBMITTER: Gaffney A

PROVIDER: S-EPMC6614229 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The Incidence of Diabetic Ketoacidosis During "Emerging Adulthood" in the USA and Canada: a Population-Based Study.

Gaffney Adam A Christopher Andrea A Katz Alan A Chateau Dan D McDougall Chelsey C Bor David D Himmelstein David D Woolhandler Steffie S McCormick Danny D

Journal of general internal medicine 20190507 7

<h4>Background</h4>As children with diabetes transition to adulthood, they may be especially vulnerable to diabetic ketoacidosis (DKA). Cross-national comparisons may inform efforts to avoid this complication.<h4>Objective</h4>To compare DKA hospitalization rates in the USA and Manitoba, Canada, during the vulnerable years known as "emerging adulthood."<h4>Design</h4>Cross-sectional study using inpatient administrative databases in the USA (years 1998-2014) and Manitoba, Canada (years 2003-2013) ...[more]

PMID: 31065950

Similar Datasets

Project description:IntroductionSodium glucose co-transporter-2 inhibitors (SGLT2) are commonly prescribed to patients with type 2 diabetes mellitus, but can increase the risk of diabetic ketoacidosis. Identifying patients prone to diabetic ketoacidosis may help mitigate this risk.MethodsWe conducted a population-based cohort study of adults initiating SGLT2 inhibitor use from 2013 through 2017. The primary objective was to identify potential predictors of diabetic ketoacidosis. Two machine-learning methods were applied to model high-dimensional pre-exposure data: gradient boosted trees and least absolute shrinkage and selection operator (LASSO) regression. We rank ordered the variables produced from LASSO by the size of their estimated coefficient (largest to smallest). With gradient boosted trees, a relative importance measure for each variable is provided rather than a coefficient. The "top variables" were identified after reviewing the distributions of the effect estimates from LASSO and gradient boosted trees to identify where there was a substantial decrease in variable importance. The identified predictors were then assessed in a logistic regression model and reported as odds ratios (ORs) with 95% confidence intervals (CIs).ResultsWe identified 111,442 adults who started SGLT2 inhibitor use. The mean age was 57 years, 44% were female, the mean hemoglobin A1C was 8.7%, and the mean creatinine was 0.89 mg/dL. During a mean follow-up of 180 days, 192 patients (0.2%, i.e., 2 per 1000) were diagnosed and hospitalized with diabetic ketoacidosis (DKA) and 475 (0.4%, i.e., 4 per 1000) were diagnosed in either an inpatient or outpatient setting. Using gradient boosted trees, the strongest predictors were prior DKA, baseline hemoglobin A1C level, baseline creatinine level, use of medications for dementia, and baseline bicarbonate level. Using LASSO regression not including laboratory test results due to missing data, the strongest predictors were prior DKA, digoxin use, use of medications for dementia, and recent hypoglycemia. The logistic regression model incorporating the variables identified from gradient boosted trees and LASSO regression suggested the following pre-exposure characteristics had the strongest association with a hospitalization for DKA: use of dementia medications (OR = 7.76, 95% CI 2.60, 23.1), prior intracranial hemorrhage (OR = 11.5, 95% CI 1.46, 91.1), a prior diagnosis of hypoglycemia (OR = 5.41, 95% CI 1.92,15.3), prior DKA (OR = 2.45, 95% CI 0.33, 18.0), digoxin use (OR = 4.00, 95% CI 1.21, 13.2), a baseline hemoglobin A1C above 10% (OR = 3.14, 95% CI 1.95, 5.06), and baseline bicarbonate below 18 mmol/L (OR 5.09, 95% CI 1.58, 16.4).ConclusionDiabetic ketoacidosis affected approximately 2 per 1000 patients starting to use an SGLT2 inhibitor. We identified both anticipated, e.g., low baseline serum bicarbonate, and unanticipated, e.g., digoxin, dementia medications, risk factors for SGLT2 inhibitor-induced DKA.

Project description:BackgroundCutaneous melanoma (CM) is one of the most fatal types of skin cancer. Alarmingly, increases in incidence and mortality were noted globally for this malignancy, despite increase in understanding of melanoma pathogenesis and enhanced prevention efforts.MethodsData was extracted for CM patients for provinces and territories (except Quebec) using two independent, population-based registries. Analysis was performed using both clinical and pathological characteristics: tumor morphologic classification, age, sex, anatomic site affected and place of residence. Mortality trends were assessed over a 7-year period. Results were compared to prior findings for 1992-2010.ResultsDuring 2011-2017 39,610 patients were diagnosed with CM, with 5,890 reported deaths. National crude CM incidence was 20.75 (age-standardized incidence: 14.12) cases per 100,000 individuals per year. Females accounted for 45.8% of cases and 37.1% of deaths. While CM incidence rates continue to increase in both sexes, since 2013 the CM mortality is declining. We observed important differences across the provinces/territories, where Nova Scotia, Prince Edward Island, southern Ontario/British Columbia and certain coastal communities of New Brunswick demonstrated higher CM incidence and mortality rates. The observed incidence and mortality trends for 2011-2017 validate and extend earlier observations from 1992 to 2010 for CM.ConclusionThis population-based study highlights that while melanoma's incidence is increasing in Canada, mortality rates are for the first time decreasing since 2013. We detail regional distribution of this cancer highlighting communities in southern/coastal areas, as being most at risk as well as the latest trends of melanoma incidence by age, sex and anatomic site. In males, melanoma is more common on the head/trunk, while in females on the extremities. Notably, Acral Lentiginous Melanoma was the only CM subtype that was more common in females, which primarily affects hands and feet.

Dataset Information

The Incidence of Diabetic Ketoacidosis During "Emerging Adulthood" in the USA and Canada: a Population-Based Study.

Background

Objective

Design

Participants

Main measures

Key results

Conclusions

Publications

The Incidence of Diabetic Ketoacidosis During "Emerging Adulthood" in the USA and Canada: a Population-Based Study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets